Bain Capital, a prominent buyout firm, is currently in discussions to acquire contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, as reported by Bloomberg News on Friday. The potential deal involves Bain Capital purchasing a majority stake in PCI from its current backers, which include Kohlberg & Co, Mubadala Investment Co, and Partners Group Holding AG.
PCI Pharma Services, based in Philadelphia, specializes in fill-finish work for drugmakers, which includes the filling and packaging of syringes and injection pens in sterile conditions. Additionally, the company offers various tools and services to aid in the research and development of new drugs. Despite the significant role PCI plays in the pharmaceutical industry, a representative for the company declined to comment on the ongoing discussions with Bain Capital.
In order to finance the equity portion of the deal, Bain has reportedly been reaching out to potential co-investors, including sovereign wealth funds. This strategic move aims to secure the necessary funding for the acquisition of PCI Pharma Services.
The potential acquisition of PCI by Bain Capital highlights the growing interest in contract drug manufacturing services within the pharmaceutical sector. As the demand for specialized drug services continues to rise, companies like PCI are positioned to play a crucial role in supporting drug development and production processes.
The news of Bain Capital’s talks with PCI Pharma Services underscores the dynamic nature of the pharmaceutical industry and the strategic partnerships that are formed to drive innovation and growth. With the potential acquisition of PCI, Bain Capital aims to further strengthen its presence in the pharmaceutical sector and capitalize on the opportunities presented by the evolving healthcare landscape.
This article, based on the original report from Reuters, provides insights into the latest developments in the pharmaceutical industry and the potential impact of the proposed acquisition of PCI Pharma Services by Bain Capital. Stay tuned for further updates on this developing story.
